biowaiver for higher strength [Regulatives / Guidelines]

posted by jag009  – NJ, 2022-01-24 16:09 (757 d 10:08 ago) – Posting: # 22753
Views: 2,081

HI Dshah,

❝ Interesting question but when we revisit guidelines, the biowaiver recommendation is mostly for lower strength formulation only. I believe that the criteria of not using higher strength due to safety/AE if justifiable, then may be used to support waiver using lower strength.


According to the guidance it seems possible.
"For an NDA, biowaivers of a higher strength will be determined to be appropriate based on (1) clinical safety and/or efficacy studies including data on the dose and the desirability of the higher strength, (2) linear elimination kinetics over the therapeutic dose range, (3) the higher strength being proportionally similar to the lower strength, and (4) the same dissolution procedures being used for both strengths and similar dissolution results obtained. A dissolution profile should be generated for all strengths."

thx
John

Complete thread:

UA Flag
Activity
 Admin contact
22,899 posts in 4,806 threads, 1,651 registered users;
21 visitors (0 registered, 21 guests [including 6 identified bots]).
Forum time: 02:18 CET (Europe/Vienna)

Statistics is, or should be, about scientific investigation
and how to do it better, but many statisticians believe
it is a branch of mathematics.    George E.P. Box

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5